Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11050103 | 0.98 | MEN1 (0.66) | MEN1KMT2AGPR84ABL1RIN1 | |
| Oxiniacic Acid SCHEMBL129209 | 0.81 | MEN1 (1.00) | MEN1KMT2AGPR84ABL1RIN1 | |
| Oxiniacic Acid SCHEMBL29766756 | 0.81 | MEN1 (1.00) | MEN1KMT2AGPR84ABL1RIN1 | |
| SCHEMBL29618255 | 0.79 | MEN1 (0.68) | MEN1KMT2AGPR84ABL1RIN1 | |
| SCHEMBL128526 | 0.79 | MEN1 (0.68) | MEN1KMT2AGPR84ABL1RIN1 | |
| SCHEMBL212234 | 0.79 | MEN1 (0.68) | MEN1KMT2AGPR84ABL1RIN1 | |
| SCHEMBL9083270 | 0.79 | MEN1 (0.68) | MEN1KMT2AGPR84ABL1RIN1 | |
| SCHEMBL10920085 | 0.78 | MEN1 (0.71) | MEN1KMT2AGPR84ABL1RIN1 | |
| SCHEMBL10899428 | 0.78 | MEN1 (0.71) | MEN1KMT2AGPR84ABL1RIN1 | |
| Maleic Acid SCHEMBL19463946 | 0.76 | KMT2A (0.57) | MEN1KMT2AGPR84ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | disclosed |
| CN-101878212-A | Triazolopyridine compounds and their use as ask inhibitors | SERONO LAB | 2010-11-03 | — | — | CN | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
| US-4501747-A | ANTIHISTAMINES | SANOFI (FR) | 1985-02-26 | — | — | US | disclosed |
| US-4110324-A | HYPOLIPIDEMIC | GUERITEE NICOLAS | 1978-08-29 | — | — | US | disclosed |
| US-4068074-A | BACTERICIDES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1978-01-10 | — | — | US | disclosed |
| US-4042581-A | HYPOLIPIDEMIC AGENTS | GUERITEE NICOLAS | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | MEN1 3192/4885KMT2A 2653/4885GPR84 2561/4885 |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MAP3K5, MAPKAPK5, MAP3K9 | MEN1 3192/4885KMT2A 2653/4885GPR84 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.